Retatrutides Phase 2 monotherapy weight loss (~24.2% at 48 weeks) is numerically larger than cagrilintides (~10.8% at 26 weeks), but those come from different trials, durations, and doses, and cagrilintides strongest data are as the CagriSema combination
While these results were not statistically significant, researchers say the small sample size in this study could have skewed those results
Refrigeration maintains the solution in a stable, liquid state, ensuring it remains perfectly mixed and ready for use
Field of use: Vitamin B12deficiency that cannot be remedied nutritionally
In diet-induced obese (DIO) mouse models, 5-Amino-1MQ treatment produced significant reductions in body weight, white adipose tissue mass, and adipocyte cell size without significant effects on food intake suggesting a metabolic rather than appetite-suppressing mechanism